Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
NCT06455124

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Led by Fudan University · Updated on 2024-06-13

60

Participants Needed

1

Research Sites

294 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a single arm phase II study to explore the 3y LRFS and safety for high-risk early rectal cancer after local excision with short-course radiotherapy and chemo-immunotherapy.

CONDITIONS

Official Title

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 75 years, both female and male
  • Pathologically confirmed adenocarcinoma
  • Tumor located 7 cm or less from the anal verge
  • pT1 stage after local excision with at least one high-risk feature such as margin positivity or very close margin (<1 mm), depth of invasion >1 mm or SM3 invasion, high-grade or poorly differentiated tumor, lymphovascular invasion, perineural invasion, tumor budding, or pT2 tumor
  • Refusal of radical surgery
  • No pelvic or distant metastases
  • Karnofsky Performance Status (KPS) of 70 or higher
  • Good treatment compliance
  • Microsatellite stable (MSS) or proficient mismatch repair (pMMR) status
  • No previous anti-cancer therapy or immunotherapy
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women
  • Pathologically confirmed signet ring cell carcinoma
  • History of other malignancies within the past 5 years
  • Serious medical illnesses such as severe mental disorders, cardiac disease, or uncontrolled infection
  • Immunodeficiency or long-term use of immunosuppressive agents
  • Blood and biochemical test results outside specified ranges: neutrophils <1.5 x 10^9/L, hemoglobin <90 g/L, platelets <100 x 10^9/L, ALT/AST >2.5 times upper limit of normal, creatinine >1 times upper limit of normal
  • DPD deficiency
  • Allergy to any component of the therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fudan University Shanghai Cancer Center

Shanghai, China

Actively Recruiting

Loading map...

Research Team

Z

Zhen Zhang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here